NCT03815058: An ongoing trial by Genentech, Inc.
This trial is ongoing. It must report results 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03815058 |
|---|---|
| Title | A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced Melanoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 8, 2019 |
| Completion date | Jan. 21, 2025 |
| Required reporting date | Jan. 21, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |